Haura Eric B, Sotomayor Eduardo, Antonia Scott J
Thoracic Oncology Program, The H. Lee Moffitt Cancer Center and Research Institute. MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA.
Mol Biotechnol. 2003 Oct;25(2):139-48. doi: 10.1385/MB:25:2:139.
Lung cancer continues to be the largest killer of Americans due to cancer. Although progress has been made, with advances in chemotherapy, the majority of patients diagnosed with lung cancer ultimately succumb to the disease. A better understanding of the molecular pathogenesis of lung cancer is demonstrating how alterations in oncogenes and tumor suppressor genes control lung cancer initiation, growth, and survival. In this article, attempts to target molecular alterations in lung cancer using gene therapy techniques are reviewed. These include introducing suicide genes into tumor cells, replacement of defective tumor suppressor genes, inactivating oncogenes, and immunotherapy-based approaches using gene therapy technology. The major barrier for these techniques continues to be the inability to specifically target tumor cells while sparing normal cells. Nonetheless, these approaches are likely to yield important biologic and clinical data which will further the progress of lung cancer treatment.
肺癌仍是美国人因癌症死亡的首要原因。尽管在化疗方面取得了进展，但大多数被诊断为肺癌的患者最终仍死于该疾病。对肺癌分子发病机制的深入了解正在揭示癌基因和肿瘤抑制基因的改变如何控制肺癌的发生、发展和存活。本文综述了利用基因治疗技术针对肺癌分子改变的尝试。这些尝试包括将自杀基因导入肿瘤细胞、替换缺陷的肿瘤抑制基因、使癌基因失活以及使用基因治疗技术的基于免疫疗法的方法。这些技术的主要障碍仍然是无法在不损伤正常细胞的情况下特异性地靶向肿瘤细胞。尽管如此，这些方法可能会产生重要的生物学和临床数据，从而推动肺癌治疗的进展。
